Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Net Income (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Net Income for 14 consecutive years, with -$32.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 43.84% year-over-year to -$32.5 million, compared with a TTM value of -$136.7 million through Dec 2025, up 29.19%, and an annual FY2025 reading of -$136.7 million, up 29.19% over the prior year.
  • Net Income was -$32.5 million for Q4 2025 at Fate Therapeutics, down from -$32.2 million in the prior quarter.
  • Across five years, Net Income topped out at -$24.9 million in Q1 2023 and bottomed at -$84.6 million in Q3 2022.
  • Average Net Income over 5 years is -$51.1 million, with a median of -$46.8 million recorded in 2023.
  • The sharpest move saw Net Income tumbled 109.01% in 2021, then surged 66.38% in 2023.
  • Year by year, Net Income stood at -$69.1 million in 2021, then grew by 10.92% to -$61.5 million in 2022, then rose by 29.05% to -$43.7 million in 2023, then crashed by 32.55% to -$57.9 million in 2024, then soared by 43.84% to -$32.5 million in 2025.
  • Business Quant data shows Net Income for FATE at -$32.5 million in Q4 2025, -$32.2 million in Q3 2025, and -$34.0 million in Q2 2025.